研究经皮闭合左心耳和华法林对房颤预防脑卒中影响的课件.pptVIP

下载本文档

4
0
约1.18万字
约 27页
2018-06-22 发布于贵州
举报
版权申诉

研究经皮闭合左心耳和华法林对房颤预防脑卒中影响的课件.ppt

1、有哪些信誉好的足球投注网站（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

研究经皮闭合左心耳和华法林对房颤预防脑卒中影响的课件

PROTECT AF研究：经皮闭合左心耳和华法林对房颤预防脑卒中影响的前瞻性随机研究 PROTECT AF trials：Randomized Prospective Trial of Percutaneous LAA Closure vs Warfarin for Stroke Prevention in AF David Holmes, MD;Vivek Reddy, MD; Zoltan Turi, MD，et al Relevant Financial Relationship(s) Mayo receives research support from Atritech and may receive royalties PROTECT AF Trial Sponsor: Atritech (Plymouth, MN) Principal Investigator: David Holmes Clinical Trials Indentifier: NCProspective, Multicenter Randomized Trial of Percutaneous Left Atrial Appendage Occlusion vs Long-term Warfarin Therapy in Patients with Non-Valvular Atrial Fibrillation Facts about Atrial Fibrillation (AF) AF is the most common cardiac arrhythmia Affects more than 3 million individuals in the US Projected to increase to 16 million by 2050 Patients with AF have a 5-fold higher risk of stroke Over 87% of strokes are thromboembolic Greater than 90% of thrombus accumulation originates in the Left Atrial Appendage (LAA) Stroke is the number one cause of long-term disability and the third leading cause of death in patients with AF Non-Valvular Atrial Fibrillation Stroke PreventionMedical Rx 3000838-10 Cooper: Arch Int Med 166, 2006Lip: Thromb Res 118, 2006 Warfarin cornerstone of therapy Assuming 51 ischemic strokes/1000 pt-yr Adjusted standard dose warfarin prevented 28 strokes at expense of 11 fatal bleeds Aspirin prevented 16 strokes at expense of 6 fatal bleeds Warfarin 60-70% risk reduction vs no treatment 30-40% risk reduction vs aspirin Challenges in Treating AF However warfarin is not always well-tolerated Narrow therapeutic range (INR between 2.0 – 3.0) Effectiveness is impacted by interactions with some foods and medications Requires frequent monitoring and dose adjustments Published reports indicate that less than 50% of patients eligible are being treated with warfarin due to tolerance or non-compliance issues SPORTIF trials suggest only 60% of patients treated are within a therapeutic INR range, w